Antiviral therapy for chronic hepatitis C: Past, present, and future

Journal of Gastroenterology

Volumn 41, Issue 1, 2006, Pages 17-27

  Hayashi, Norio ^a   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANA 975; ANTIVIRUS AGENT; CPG 10101; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; INTERFERON REGULATORY FACTOR 3; ISATORBINE; NM 283; NUCLEOSIDE ANALOG; PEGINTERFERON; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAMIDINE; RIBAVIRIN; SCH 503034; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS RNA; VX 950;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; BLEEDING; CANCER RISK; CANCER SCREENING; CHRONIC HEPATITIS; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENOTYPE; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INCIDENCE; LEUKOPENIA; LIVER BIOPSY; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG FIBROSIS; MONOTHERAPY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL SIGNIFICANCE; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 33644547392     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-005-1740-7     Document Type: Review

References (69)

1. QL Choo G Kuo AJ Weiner LR Overby DW Bradley M Houghton 1989 Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 359-62 1:CAS:528:DyaL1MXit1Khtrk%3D 2523562
2. Anonymous 1999 Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 6 35-47
3. JH Hoofnagle KD Mullen DB Jones V Rustgi A Di Bisceglie M Peters 1986 Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report N Engl J Med 315 1575-8 1:STN:280:BiiD28vptlU%3D 3097544
4. GL Davis LA Balart ER Schiff K Lindsay HC Bodenheimer Jr RP Perrillo 1989 Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial N Engl J Med 321 1501-6 1:STN:280:By%2BD2czptFI%3D 2509916
5. AM Di Bisceglie P Martin C Kassianides M Lisker-Melman L Murray J Waggoner 1989 Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1506-10 1:STN:280:By%2BD2czptFM%3D 2509917
6. H Hagiwara N Hayashi E Mita K Ueda T Takehara A Kasahara 1992 Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α Hepatology 15 37-41 1:STN:280:By2D1M%2FpslY%3D 1370161
7. H Hagiwara N Hayashi E Mita T Takehara A Kasahara H Fusamoto 1993 Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy Gastroenterology 104 877-883 1:STN:280:ByyC2sfosVM%3D 8382646
8. E Mita N Hayashi H Hagiwara K Ueda Y Kanazawa A Kasahara 1994 Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer Dig Dis Sci 39 977-982 10.1007/BF02087547 1:STN:280:ByuB38fptVQ%3D 7909743
9. A Kasahara N Hayashi N Hiramatsu M Oshita H Hagiwara K Katayama 1995 Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial Hepatology 21 291-7 10.1016/ 0270-9139(95)90083-7 1:STN:280:ByqC2cngt1M%3D 7843696
10. P Marcellin N Boyer E Giostra C Degott AM Courouce F Degos 1991 Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France Hepatology 13 393-7 10.1016/0270-9139(91)90288-7 1:STN:280:By6C2Mzns1Y%3D 1900254
11. X Causse H Godinot M Chevallier P Chossegros F Zoulim D Ouzan 1991 Comparison of 1 or 3MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 101 497-502 1:STN:280:By6B1MzltFA%3D 1906028
12. KL Lindsay GL Davis ER Schiff HC Bodenheimer LA Balart JL Dienstag 1996 Response to higher dose of interferon alpha-2b in patients with chronic hepatitis C: A randomized multicenter trial. Hepatitis Interventional Therapy Group Hepatology 24 1034-40 1:STN:280:ByiD28%2FjtlI%3D 8903371
13. T Poynard V Leroy M Cohard T Thevenot P Mathurin P Opolon 1996 Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effect of dose and duration Hepatology 24 778-89 1:CAS:528:DyaK28XmvFOisb4%3D 8855176
14. NC Tassopoulos G Karvountzis G Touloumi JK Delladetsima GV Papatheodoridis A Katsoulidou 1996 Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: A randomized controlled trial Am J Gastroenterol 91 1734-8 1:CAS:528:DyaK28XlvVGqsLc%3D 8792690
15. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo 1998 Randomized trial of interferon alpha-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1426-32 10.1016/ S0140-6736(98)07124-4 1:CAS:528:DyaK1cXnsVSmsLg%3D 9807989
16. JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi 1998 Interferon alpha-2b and ribavirin as initial treatment of relapse of chronic hepatitis C N Engl J Med 339 1485-92 10.1056/NEJM199811193392101 1:CAS:528:DyaK1cXnslGmtbs%3D 9819446
17. N Hiramatsu A Kasahara F Nakanishi T Toyama M Tsujii S Tsuji 2004 The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan Hepatol Res 29 142-7 1:CAS:528:DC%2BD2cXltVGgsrc%3D 15203077
18. M Rumi E Del Ninno ML Parravicini R Romeo R Soffredini MF Donato 1996 A prospective randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C Hepatology 24 1366-70 1:CAS:528:DyaK2sXpt1Cmtg%3D%3D 8938163
19. MJ Tong KR Reddy WM Lee PJ Pockros JC Hoefs EB Keeffe 1997 Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Consensus Interferon Group Hepatology 26 747-54 1:CAS:528:DyaK2sXmt1CktrY%3D 9303508
20. AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden 1998 Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy Science 282 103-7 10.1126/science.282.5386.103 1:CAS:528:DyaK1cXmsFOjsLc%3D 9756471
21. S Zeuzem JM Schmidt JH Lee B Ruster WK Roth 1996 Effect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo Hepatology 23 366-71 1:STN:280:BymC283gs1A%3D 8591865
22. KA Nieforth R Nadeau IH Patel D Mould 1996 Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alpha-2a and a polyethylene glycol-modified derivative in healthy subjects Clin Pharmacol Ther 59 636-46 10.1016/ S0009-9236(96)90003-X 1:CAS:528:DyaK28XksFemurY%3D 8681488
23. S Zeuzem SV Feinman J Rasenack EJ Heathcote MY Lai E Gane 2000 Peginterferon alpha-2a in patients with chronic hepatitis C N Engl J Med 343 1666-72 10.1056/NEJM200012073432301 1:CAS:528:DC%2BD3cXovVGhurY%3D 11106715
24. EJ Heathcote ML Shiffman WG Cooksley GM Dusheiko SS Lee L Balart 2000 Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 1673-80 10.1056/NEJM200012073432302 1:CAS:528:DC%2BD3cXovVGhurc%3D 11106716
25. KL Lindsay C Trepo T Heintges ML Shiffman SC Gordon JC Hoefs Hepatitis Interventional Therapy Group K Lindsay 2001 A randomized, double-blind trial comparing PEGylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 34 395-403 1:CAS:528:DC%2BD3MXmtVGqtLs%3D
26. MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindoller 2001 Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial Lancet 358 958-65 10.1016/S0140-6736(01)06102-5 1:CAS:528:DC%2BD3MXntF2qtb8%3D 11583749
27. MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales Jr 2002 Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975-82 10.1056/NEJMoa020047 1:CAS:528:DC%2BD38Xnt12rtb0%3D 12324553
28. G Dusheiko 1997 Side effects of alpha interferon in chronic hepatitis C Hepatology 26 112S-21S 10.1002/hep.510260720 1:CAS:528:DyaK2sXmt1CktL8%3D 9305675
29. HC Bodenheimer Jr KL Lindsay GL Davis JH Lewis SN Thung LB Seeff 1997 Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial Hepatology 26 473-7 10.1002/hep.510260231 1:CAS:528:DyaK2sXlsVWjur4%3D 9252161
30. GL Davis R Esteban-Mur V Rustgi J Hoefs SC Gordon C Trepo 1998 Interferon alpha-2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C N Engl J Med 339 1493-9 10.1056/NEJM199811193392102 1:CAS:528:DyaK1cXnslGmtbg%3D 9819447
31. O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O Weiland 1998 Randomized double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C Lancet 351 83-6 10.1016/S0140-6736(97)06088-1 1:CAS:528:DyaK1cXmsFSqtw%3D%3D 9439491
32. SJ Hadziyannis H Sette Jr TR Morgan V Balan M Diago P Marcellin 2004 Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346-55 1:CAS:528:DC%2BD2cXitlOktrg%3D 14996676
33. S Iino K Okita M Omata H Kumada N Hayashi K Tanikawa 2004 Clinical efficacy of PEG-Interferon α-2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load - Retrospective comparison with Interferon α-2b and ribavirin combination therapy for 24 weeks KanTanSui 49 1099-121
34. AM Di Bisceglie JH Hoofnagle 2002 Optimal therapy of hepatitis C Hepatology 36 S121-7 10.1002/hep.1840360716 12407585
35. GL Davis JB Wong JG McHutchison MP Manns J Harvey J Albrecht 2003 Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 645-52 1:CAS:528:DC%2BD3sXnvVKjt7s%3D 12939591
36. DB Strader T Wright DL Thomas LB Seeff 2004 American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C Hepatology 39 1147-71 10.1002/hep.20119 15057920
37. GL Drusano SL Preston 2004 A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus J Infect Dis 189 964-70 1:CAS:528:DC%2BD2cXjtF2mtrc%3D 14999598
38. M Buti A Valdes F Sanchez-Avila R Esteban 2003 Extending combination therapy with peginterferon alpha-2a plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases Hepatology 37 1226-7 10.1053/jhep.2003.50107 12717407
39. P Ferenci U Bergholz H Laferl C Gurguta A Maieron M Gschwantler 2005 Is shorter treatment with peginterferon alpha-2a (40KD) plus ribavirin possible in HCV genotype 1 "super-responder"? preliminary results of a prospective randomized clinical trial Hepatology 42 218A
40. A Mangia R Santoro N Minerva GL Ricci V Carretta M Persico 2005 Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2609-17 10.1056/NEJMoa042608 1:CAS:528:DC%2BD2MXls1ajsro%3D 15972867
41. M Wagner M Huber T Berg H Hinrichsen J Rasenack T Heintges 2005 Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 522-7
42. JG McHutchison M Manns K Patel T Poynard KL Lindsay C Trepo 2002 Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 1061-9 10.1053/gast.2002.35950 1:CAS:528:DC%2BD38Xotl2gurk%3D 12360468
43. NH Afdhal DT Dieterich PJ Pockros ER Schiff ML Shiffman MS Sulkowski 2004 Epoetin alpha maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study Gastroenterology 126 1302-11 10.1053/j.gastro.2004.01.027 1:CAS:528:DC%2BD2cXksF2qtLg%3D 15131791
44. PJ Pockros ML Shiffman ER Schiff MS Sulkowski Z Younossi DT Dieterich 2004 Epoetin alpha improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 1450-8 10.1002/ hep.20482 1:CAS:528:DC%2BD2MXhslaguw%3D%3D 15565613
45. P Marcellin S Levy S Erlinger 1997 Therapy of hepatitis C: Patients with normal aminotransferase levels Hepatology 26 133S-6S 10.1002/ hep.510260723 1:CAS:528:DyaK2sXmt1CktLo%3D 9305678
46. Anonymous 1999 EASL international consensus conference on hepatitis C. Consensus statement J Hepatol 30 956-62
47. L Serfaty O Chazouilleres JM Pawlotsky T Andreani C Pellet R Poupon 1996 Interferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity Gastroenterology 110 291-5 10.1053/gast.1996.v110.pm8536870 1:CAS:528:DyaK28XhtFKitbc%3D 8536870
48. A Sangiovanni R Morales G Spinzi M Rumi A Casiraghi R Ceriani 1998 Interferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study Hepatology 27 853-6 10.1002/hep.510270330 1:CAS:528:DyaK1cXhslGhs7k%3D 9500717
49. A Rossini A Ravaggi L Biasi E Agostinelli L Bercich GB Gazzola 1997 Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis Hepatology 26 1012-7 1:STN:280:ByiH28npvVw%3D 9328328
50. AM Di Bisceglie J Thompson N Smith-Wilkaitis EM Brunt BR Bacon 2001 Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of non-responders to interferon Hepatology 33 704-7 10.1053/ jhep.2001.22346 1:CAS:528:DC%2BD3MXit1emtLg%3D 11230751
51. CK Hui A Monto T Belaye E Lau TL Wright 2003 Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransferases Gut 52 1644-8 10.1136/gut.52.11.1644 1:CAS:528:DC%2BD3sXpsFyks70%3D 14570736
52. S Zeuzem M Diago E Gane KR Reddy P Pockros D Prati 2004 Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 1724-32 10.1053/j.gastro.2004.09.050 1:CAS:528:DC%2BD2MXit1Gjtg%3D%3D 15578510
53. S Zeuzem C Sarrazin R Rouzier A Tarral N Brion N Forestier 2005 Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon (PEG-IFN-α) Hepatology 42 Suppl 1 233.
54. S Zeuzem C Sarrazin F Wagner R Rouzier N Forester S Gupta 2005 Combination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1 Peg-Intron non-responder Hepatology 42 Suppl 1 233.
55. HW Reesink S Zeuzem CJ Weegink N Forester A van Vliet LA McNair 2005 Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor Hepatology 42 Suppl 1 234.
56. E Foy K Li C Wang R Sumpter Jr M Ikeda SM Lemon 2003 Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease Science 300 1145-8 10.1126/science.1082604 1:CAS:528:DC%2BD3sXjslGqtro%3D 12702807
57. E Foy K Li R Sumpter Jr YM Loo CL Johnson C Wang 2005 Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling Proc Natl Acad Sci U S A 102 2986-91 10.1073/pnas.0408707102 1:CAS:528:DC%2BD2MXitVSkt7s%3D 15710892
58. C O'Brien E Godofsky M Rodriguez-Torres N Afdhal SC Pappas P Pockros 2005 Randomized trial of valopicitabine (NM283), alone or with peginterferon, vs. retreatment with peginterferon plus ribavirin (PEGIFN/ RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: first interim results Hepatology 42 Suppl 1 234A
59. T Takehara N Hayashi 2005 Natural killer cells in hepatitis C virus infection: From innate immunity to adaptive immunity Clin Gastroenterol Hepatol 3 S78-81 10.1016/S1542-3565(05)00702-0 1:CAS:528:DC%2BD2MXhtF2ms7zP 16234066
60. BR Bacon JG McHutchison SC Gordon NH Afdhal IM Jacobson M Shiffman 2005 Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon), a novel TLR9 agonist: Comparison of normal volunteers and HCV infected individuals Gastroenterology 128 Suppl 2 P-91
61. B Kerr L Bauman S Webber A Xiang J Ng L Kirkovsky 2005 Pharmacokinetics, safety, and tolerability of the isatorbine oral prodrug ANA975 in a phase 1 healthy volunteer study Hepatology 42 Suppl 1 533A
62. JJ Feld JH Hoofnagle 2005 Mechanisms of action of interferon and ribavirin in treatment of hepatitis C Nature 436 967-72 10.1038/ nature04082 1:CAS:528:DC%2BD2MXotFent7c%3D 16107837
63. K Lindahl L Stahle A Bruchfeld R Schvarcz 2005 High-dose ribavirin in combination with standard dose PEGinterferon for treatment of patients with chronic hepatitis C Hepatology 41 275-9 10.1002/hep.20563 1:CAS:528:DC%2BD2MXhsVansbg%3D 15660393
64. RG Gish D Nelson S Arora MW Fried KR Reddy Y Xu 2005 Virologic response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alpha-2a Gastroenterology 128 Suppl 2 P-11
65. A Kasahara N Hayashi K Mochizuki M Takayanagi K Yoshioka S Kakumu 1998 Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1394-402 10.1002/hep.510270529 1:CAS:528:DyaK1cXjtVSjt7Y%3D 9581697
66. A Kasahara H Tanaka T Okanoue Y Imai H Tsubouchi K Yoshioka 2004 Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death J Viral Hepat 11 148-56 10.1046/ j.1365-2893.2003.00481.x 1:STN:280:DC%2BD2c7jvFShtA%3D%3D 14996350
67. H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata 1999 Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann Intern Med 131 174-81 1:CAS:528:DyaK1MXlsVCrtbo%3D 10428733
68. T Okanoue Y Itoh M Minami S Sakamoto K Yasui M Sakamoto 1999 Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: A retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group J Hepatol 30 653-9 10.1016/S0168-8278(99)80196-2 1:CAS:528:DyaK1MXjtVWqsbo%3D 10207807
69. Y Imai S Kawata S Tamura I Yabuuchi S Noda M Inada 1998 Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group Ann Intern Med 129 94-9 1:CAS:528:DyaK1cXlt1emsbk%3D 9669992